| |
|
|
|
Nymox Pharmaceutical Corporation  
|
|
1.6 -0.06 (-0.04%) |
12-14 16:00 |
|
Open: |
1.65 |
Pre close: |
1.66 |
Target:
|
2.31
|
|
High: |
1.7 |
Low: |
1.6 |
Resistance:
|
1.98
2.21
|
|
Volume: |
49,808 |
Market Cap: |
102M |
Support:
|
1.60
1.33
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
1.65
 |
MACD |
MACD(12,26):
|
-0.08 |
|
MA(20): |
1.77 |
Signal(12,26,9): |
-0.07 |
|
MA(100): |
2.32 |
Stochastic Oscillator |
%K(14,3):
|
11.67 |
|
MA(250): |
3.10 |
%D(3): |
15.83 |
|
Average Volume(K) |
3-Month: |
14440
|
52-Week |
High:
|
4.60 |
|
10-Days: |
7302 |
Low: |
1.49 |
|
RSI |
RSI(14):
|
38.26 |
Change(%): |
-54.7 |
|
Financials, Statistics and Valuation |
|
EPS |
0.000 |
Return on Equity (ttm) |
-568.8 |
Shares Out. (M) |
63.72 |
|
EPS Est. Current Year |
-0.200 |
Return on Assets (ttm) |
-340.4 |
Shares Float (M) |
60.55 |
|
EPS Est. Next Year |
-0.570 |
PEG Ratio |
0.00 |
% Held by Insiders |
5.50 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
29.0 |
% Held by Institutions |
10.90 |
|
Forward EPS |
1.#IO |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
0 |
|
Book Value (p.s.) |
28.370 |
EBITDA (p.s.) |
0.000 |
P/E |
0.00 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
0.06 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-7.38 |
P/S |
10195200000.00 |
|
Operating Margin |
-2908.31 |
Levered Free Cash Flow
(M) |
-3.21 |
P/CF |
-13.81 |
|
|
|
|
|
|
